ESMO 2026 | HANSOH PHARMA PRESENTED DATA FOR HS-20122 (A NOVEL EGFR/C-MET BISPECIFIC ANTIBODY DRUG CONJUGATE) FROM A FIRST-IN-HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
- HS-20122 has shown encouraging anti-tumor activities and favorable safety profiles across various types of advanced tumors.
- Promising efficacy was shown in EGFR mutant NSCLC post-EGFR TKI failure, the ORR was 61.3% and 6-month PFS rate was 75.3%, potentially making HS-20122 a novel option for this population.SHANGHAI, October 25, 2026— Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharma,” 03692.HK) today announced that the encouraging results from the Phase 1 study of HS-20122 (a novel EGFR/c-Met bispecific ADC), in patients with advanced solid tumors, were presented in the Proffered Paper Presentation session at the European Society for Medical Oncology (ESMO 2026) Congress, held in Madrid, Spain.
HS-20122 is an EGFR/c-Met bispecific targeted antibody–drug conjugate (ADC)”] under clinical development for oncology. At ESMO 2026, the data were generated from an ongoing First-in-human Phase 1 study HS-20122-101(NCT06927570) evaluating the safety, efficacy, pharmacokinetics and immunogenicity profile of HS-20122 treatment. Leading Principle Investigator of this trial is Professor Zhang Li from Sun Yat-sen University Cancer Center.
Details of the Proffered Oral presentation are as follows:
● Oral Title: HS-20122, a Novel EGFR/c-Met Bispecific Antibody Drug Conjugate, in Patients with Advanced Solid Tumors
● Session: Developmental Therapies
● Abstract No.: 1000O
● Date/Time: October 24, 2026 [CEST, UTC+2]
● Presenter: Prof. Zhao Hongyun, Department of Clinical Research, Sun Yat-sen University Cancer Center
As of data cut-off July 6, 2026, a total of 215 participants with various types of advanced solid tumors were enrolled, and the study results showed:
● Promising Efficacy: Overall Objective Response Rate among all tumor types was 44.1% and Disease Control Rate was 91.0%. Efficacy was particularly encouraging in EGFRm NSCLC post-EGFR TKI failure, with ORR 61.3% and 6-month PFS rate 75.3%, and clinical benefits were comparable in both EGFR Del19 and L858R mutation. In immuno-chemotherapy pretreated squamous NSCLC and Head and Neck Cancer, the ORR was 32.1% and 50.0%, respectively.
● Favorable Safety Profile: Overall, HS-20122 demonstrated a favorable and manageable safety profile, no DLT occurred, with most Treatment-Related Adverse Events (TRAEs) being Grade 1-2. The most common Grade ≥3 TRAEs were primarily hematological abnormalities, including neutropenia (25.6%) and decreased white blood cell count (15.8%), which were clinically manageable. EGFR/c-Met-targeted toxicities were low, with no Grade ≥3 rash and only 2 (0.9%) participants developed Grade ≥3 stomatitis.
These positive clinical findings support further development of HS-20122 in multiple solid tumors, including EGFRm NSCLC.
About HS-20122
HS-20122 is an innovative EGFR/c-Met ADC developed by Hansoh, and by combining EGFR/c-Met dual-targeting with targeted delivery of a cytotoxic payload, it is designed to provide antitumor activity in various types of solid tumors, where EGFR and c-Met signaling may contribute to disease progression or treatment resistance.
HS-20122 is developed based on HS-20117 In March 2024, the Group entered into a license agreement with Biotheus and obtained an exclusive license from Biotheus Biotechnology (Zhuhai) Co., Ltd. (“Biotheus”, acquired by BioNTech in 2025) to use bispecific antibody targeting EGFR/c-MET, including HS-20117, globally for the development, production and commercialization of ADC products, with the right of sublicense.
About Advanced Solid Tumor and NSCLC
In 2022, there were nearly 20 million new cancer cases and about 9.7 million deaths worldwide.[1] China recorded 4.82 million new cases and 2.57 million deaths, representing roughly 24% of global cases and 26% of deaths.[2]
Non-small cell lung cancer (NSCLC) comprises around 85% of lung cancers, is the leading cause of cancer incidence and death globally.[1] Worldwide, lung cancer accounted for 2.48 million new cases and 1.82 million deaths.[3] In China, figures were 1.06 million cases and 0.73 million deaths (over 40% of the global lung cancer burden) and the majority of NSCLC cases were diagnosed at advanced stages.[3]
References
1.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
2.Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024 Feb 2;4(1):47-53.
3.Ding YM,et al.[Epidemiological characteristics of lung cancer in China and worldwide]. Zhonghua Zhong Liu Za Zhi. 2025;47(9):850-857.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
